Mối liên hệ giữa glucose huyết lúc đói và nguy cơ mắc suy tim trong suốt đời: Dự án Tổng hợp Nguy cơ Vĩnh viễn

Springer Science and Business Media LLC - 2021
Arjun Sinha1, Hongyan Ning2, Faraz Ahmad1, Michael P. Bancks3, Mercedes R. Carnethon4, Matthew J. O’Brien5, Norrina B Allen2, John T. Wilkins1, Donald M. Lloyd‐Jones1, Sadiya S. Khan2
1Division of Cardiology, Department of Medicine and Preventive Medicine, Northwestern University Feinberg School of Medicine, 680 N. Lake Shore Drive, 14-002, Chicago, IL, 60611, USA
2Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
3Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA
4Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL USA
5Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Tóm tắt

Tóm tắt Đặt vấn đề Trước tình trạng gia tăng tỷ lệ mắc chứng rối loạn đường huyết và sự chênh lệch trong gánh nặng suy tim (HF), chúng tôi đã xác định nguy cơ mắc HF suốt đời theo từng chủng tộc và giới tính trên phổ glucose huyết lúc đói (FPG). Phương pháp Dữ liệu ở cấp độ cá nhân từ các cá nhân trưởng thành không có tiền sử mắc HF đã được gộp lại từ 6 nhóm khảo sát dựa trên dân số. Phân tích Kaplan–Meier đã được điều chỉnh, mô hình Cox đã điều chỉnh cho nguy cơ cạnh tranh từ cái chết, và trung bình giới hạn của Irwin được sử dụng để ước lượng nguy cơ suốt đời, tỷ lệ nguy cơ điều chỉnh (aHR) và số năm sống mà không bị HF ở những người trưởng thành trung niên (40–59 tuổi) và cao tuổi (60–79 tuổi) với FPG < 100 mg/dL, tiền tiểu đường (FPG 100–125 mg/dL) và tiểu đường (FPG ≥ 126 mg/dL hoặc đang sử dụng thuốc hạ đường huyết) giữa các nhóm chủng tộc-giới tính.

Từ khóa

#suy tim #rối loạn đường huyết #nguy cơ suốt đời #tiền tiểu đường #glucose huyết lúc đói

Tài liệu tham khảo

Barzilay JI, Kronmal RA, Gottdiener JS, Smith NL, Burke GL, Tracy R, et al. The association of fasting glucose levels with congestive heart failure in diabetic adults > or =65 years: the cardiovascular health study. J Am Coll Cardiol. 2004;43(12):2236–41. https://doi.org/10.1016/j.jacc.2003.10.074.

Kannel WB, D’Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159(11):1197–204. https://doi.org/10.1001/archinte.159.11.1197.

Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879–84. https://doi.org/10.2337/diacare.27.8.1879.

Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241(19):2035–8. https://doi.org/10.1001/jama.241.19.2035.

He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996–1002. https://doi.org/10.1001/archinte.161.7.996.

Ahmad FS, Ning H, Rich JD, Yancy CW, Lloyd-Jones DM, Wilkins JT. Hypertension, obesity, diabetes, and heart failure-free survival: the cardiovascular disease lifetime risk pooling project. JACC Heart Fail. 2016;4(12):911–9. https://doi.org/10.1016/j.jchf.2016.08.001.

Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007;115(11):1371–5. https://doi.org/10.1161/circulationaha.106.661405.

Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes. 2010;59(8):2020–6. https://doi.org/10.2337/db10-0165.

Nielson C, Lange T. Blood glucose and heart failure in nondiabetic patients. Diabetes Care. 2005;28(3):607–11. https://doi.org/10.2337/diacare.28.3.607.

Deedwania P, Patel K, Fonarow GC, Desai RV, Zhang Y, Feller MA, et al. Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: findings from a population-based cohort study. Int J Cardiol. 2013;168(4):3616–22. https://doi.org/10.1016/j.ijcard.2013.05.038.

Hubbard D, Colantonio LD, Tanner RM, Carson AP, Sakhuja S, Jaeger BC, et al. Prediabetes and risk for cardiovascular disease by hypertension status in black adults: the jackson heart study. Diabetes Care. 2019;42(12):2322–9. https://doi.org/10.2337/dc19-1074.

Banerjee D, Biggs ML, Mercer L, Mukamal K, Kaplan R, Barzilay J, et al. Insulin resistance and risk of incident heart failure: cardiovascular health study. Circ Heart Fail. 2013;6(3):364–70. https://doi.org/10.1161/circheartfailure.112.000022.

Prevention. CfDCa. National diabetes statistics report: estimates of diabetes and its burden in the United States. 2020.

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation. 2019;139(10):e56–528. https://doi.org/10.1161/cir.0000000000000659.

Karmali KN, Lloyd-Jones DM. Adding a life-course perspective to cardiovascular-risk communication. Nat Rev Cardiol. 2013;10(2):111–5. https://doi.org/10.1038/nrcardio.2012.185.

Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-Jones DM. Lifetime risk and years lived free of total cardiovascular disease. JAMA. 2012;308(17):1795–801. https://doi.org/10.1001/jama.2012.14312.

Abdel-Qadir H, Fang J, Lee DS, Tu JV, Amir E, Austin PC, et al. Importance of considering competing risks in time-to-event analyses: application to stroke risk in a retrospective cohort study of elderly patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2018;11(7):e004580. https://doi.org/10.1161/circoutcomes.118.004580.

Glynn P, Lloyd-Jones DM, Feinstein MJ, Carnethon M, Khan SS. Disparities in cardiovascular mortality related to heart failure in the United States. J Am Coll Cardiol. 2019;73(18):2354–5. https://doi.org/10.1016/j.jacc.2019.02.042.

Chang PP, Wruck LM, Shahar E, Rossi JS, Loehr LR, Russell SD, et al. Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005–2014): ARIC study community surveillance. Circulation. 2018;138(1):12–24. https://doi.org/10.1161/CIRCULATIONAHA.117.027551.

Zareini B, Blanche P, D’Souza M, Elmegaard Malik M, Nørgaard CH, Selmer C, et al. Type 2 diabetes mellitus and impact of heart failure on prognosis compared to other cardiovascular diseases: a nationwide study. Circ Cardiovasc Qual Outcomes. 2020. https://doi.org/10.1161/circoutcomes.119.006260.

Shang Y, Marseglia A, Fratiglioni L, Welmer A-K, Wang R, Wang H-X, et al. Natural history of prediabetes in older adults from a population-based longitudinal study. J Intern Med. 2019;286(3):326–40. https://doi.org/10.1111/joim.12920.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9. https://doi.org/10.1016/s0140-6736(18)32590-x.

Wilkins JT, Karmali KN, Huffman MD, Allen NB, Ning H, Berry JD, et al. Data resource profile: the cardiovascular disease lifetime risk pooling project. Int J Epidemiol. 2015;44(5):1557–64. https://doi.org/10.1093/ije/dyv150.

Bancks MP, Ning H, Allen NB, Bertoni AG, Carnethon MR, Correa A, et al. Long-term absolute risk for cardiovascular disease stratified by fasting glucose level. Diabetes Care. 2019;42(3):457–65. https://doi.org/10.2337/dc18-1773.

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. https://doi.org/10.1080/01621459.1999.10474144.

Karrison TG. Use of Irwin’s restricted mean as an index for comparing survival in different treatment groups—interpretation and power considerations. Control Clin Trials. 1997;18(2):151–67. https://doi.org/10.1016/s0197-2456(96)00089-x.

Arnlöv J, Lind L, Zethelius B, Andrén B, Hales CN, Vessby B, et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J. 2001;142(4):720–4. https://doi.org/10.1067/mhj.2001.116957.

Arnlöv J, Lind L, Sundström J, Andrén B, Vessby B, Lithell H. Insulin resistance, dietary fat intake and blood pressure predict left ventricular diastolic function 20 years later. Nutr Metab Cardiovasc Dis. 2005;15(4):242–9. https://doi.org/10.1016/j.numecd.2004.10.002.

Fang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol. 2003;41(4):611–7. https://doi.org/10.1016/s0735-1097(02)02869-3.

Tseng E, Yeh HC, Maruthur NM. Metformin use in prediabetes among US adults, 2005–2012. Diabetes Care. 2017;40(7):887–93. https://doi.org/10.2337/dc16-1509.

American Diabetes Association. 3. Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S29–33. https://doi.org/10.2337/dc19-S003.

Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279–90. https://doi.org/10.1016/s0140-6736(12)60283-9.

Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. https://doi.org/10.1056/NEJMoa1511939.

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. https://doi.org/10.1056/NEJMoa012512.

Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study. Lancet Diabetes Endocrinol. 2015;3(11):866–75. https://doi.org/10.1016/s2213-8587(15)00291-0.

Kalinowski J, Taylor JY, Spruill TM. Why are young black women at high risk for cardiovascular disease? Circulation. 2019;139(8):1003–4. https://doi.org/10.1161/circulationaha.118.037689.

Xiang AH, Li BH, Black MH, Sacks DA, Buchanan TA, Jacobsen SJ, et al. Racial and ethnic disparities in diabetes risk after gestational diabetes mellitus. Diabetologia. 2011;54(12):3016–21. https://doi.org/10.1007/s00125-011-2330-2.

American Psychological Association AWGoSaHD. Stress and health disparities: contexts, mechanisms, and interventions among racial/ethnic minority and low-socioeconomic status populations. 2017.

McSweeney JC, Rosenfeld AG, Abel WM, Braun LT, Burke LE, Daugherty SL, et al. Preventing and experiencing ischemic heart disease as a woman: state of the science: a scientific statement from the American heart association. Circulation. 2016;133(13):1302–31. https://doi.org/10.1161/cir.0000000000000381.

Victor RG, Blyler CA, Li N, Lynch K, Moy NB, Rashid M, et al. Sustainability of blood pressure reduction in black barbershops. Circulation. 2019;139(1):10–9. https://doi.org/10.1161/circulationaha.118.038165.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả